Lilly to spend more than $1B to expand operations in India
Indianapolis-based Eli Lilly and Co. said the investment will strengthen its manufacturing and supply capabilities to support its growing portfolio of drugs.
Eli Lilly and Co.
Articles
Drugmakers buoyed as Trump deal eases worst fears on pricing
Shares in Indianapolis-based Eli Lilly and Co. were on the rise Wednesday after President Trump suggested the company would be next up to cut a deal over drug pricing.
Trump to announce drug-pricing deal with Pfizer, new ‘TrumpRx’ website
The announcements are part of an effort to secure “Most Favored Nation” pricing deals with pharmaceutical manufacturers, an effort to link U.S. drug prices to the lowest cost of drugs paid by the wealthiest countries.
What new tariffs mean for pharmaceuticals, patented drugs
President Donald Trump’s announcement that his administration will impose a 100 percent tariff on patented pharmaceutical products sparked confusion Friday, as government officials, drug companies and trade groups sought clarity on how the levy would be applied.
Eli Lilly plans to make highly anticipated weight-loss pill at new $6.5B Texas plant
The $6.5 billion Houston-area plant is part of the drugmaker’s commitment to add four U.S. manufacturing sites through a $27 billion reshoring investment unveiled early this year.
Pfizer amps up push into obesity treatments with $4.9B deal for Metsera
Demand for obesity treatments has soared recently, due to unprecedented weight loss provided by regular injections of market leaders Wegovy from Novo Nordisk and Zepbound from Indianapolis-based Eli Lilly and Co.
Lilly brain health campaign aims to ward off dementia
Eli Lilly and Co. this month launched a public awareness campaign called Brain Health Matters, which features actress Julianne Moore urging people to be proactive as they age to lower their risk of dementia, including Alzheimer’s disease.
Trial shows Lilly rival’s weight-loss pill could deliver same results as shots as companies race to market
Ahead of decisions by the FDA, both Novo Nordisk and Eli Lilly are readying production for their weight-loss pills, having been unable to keep up with demand for their shots that exploded in popularity.
Lilly’s GLP-1 pill beats older Novo diabetes drug in head-to-head trial
Eli Lilly and Co. and Novo Nordisk have been locked in a fierce battle to control the obesity market, which is projected to reach $100 billion by the end of the decade.
FDA takes aim at Hims and other telehealth services in drug advertising crackdown
The Food and Drug Administration on Tuesday posted more than 100 letters to various drug and online prescribing companies, including Hims & Hers, which has built a multibillion-dollar business centered on lower-cost versions of blockbuster obesity injections.
Eli Lilly to build $5B plant in Virginia—first of 4 U.S. sites to be named this year
Indianapolis-based Lilly said the new plant would create more than 650 jobs in Virginia for engineers, scientists, operations personnel and lab technicians, as well as 1,800 construction jobs.
Lilly rival Novo Nordisk, maker of obesity drug Wegovy, to cut 9,000 jobs
The restructuring, which would eliminate 11% of the company’s workforce, aimed to reduce organizational complexity and speed up decision-making as the company faces a more competitive market for obesity drugs.
World Health Organization adds Mounjaro to its list of essential medicines
The recommendation applies to a range of GLP-1 drugs that also includes Novo Nordisk’s Ozempic and Lilly’s older diabetes treatment, Trulicity.
Mounjaro price hike fuels UK pharmacy battle to retain customers
Eli Lilly and Co. announced this month it would raise the weight-loss treatment’s price by as much as 170%, presenting pharmacies with a dilemma about how much they would pass on to patients.
Lilly’s weight-loss pill moves ahead after pivotal trial
The company’s shares rose as much as 4.3% Tuesday after Eli Lilly announced the trial results for orforglipron.
Ireland’s exports to US plunge after tariff-induced surge, likely related to pharma stockpiling
Indianapolis-based Eli Lilly and Co. has operated in Ireland since the late 1970s and has more than 3,500 employees there.
Lilly signs $1.3B deal with Boston startup for AI-assisted drug development
Superluminal will use its AI-driven platform to discover and optimize small-molecule treatments for G protein-coupled receptors, or GPCRs, which have emerged as a key to conditions such as diabetes and obesity.
Lilly hikes obesity shot price in UK as Trump pressures drugmakers
Trump sent letters to 17 of the world’s largest drugmakers earlier this month, including Lilly and Novo Nordisk A/S, insisting they lower what they charge Medicaid in the U.S. for existing drugs.
Texas AG: Eli Lilly and Co. offered kickbacks to providers to prescribe blockbuster drugs
The complaint alleges the Indianapolis-based drugmaker offered illegal incentives to influence Texas providers to prescribe Lilly medications including Zepbound and Mounjaro.
Firm tied to Trump Jr. debuts direct sales product for pharma companies
Eli Lilly and Co. has already launched LillyDirect service, which CEO David Ricks says jibes with the administration’s demand for direct sales. Lilly is working with Truepill and Amazon.com Inc.’s pharmacy unit on its platform.